Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4456MR)

This product GTTS-WQ4456MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4456MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3665MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ11273MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ15065MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ8740MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ4067MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ7338MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ11811MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ1004MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-383
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW